Regeneron Pharmaceuticals, Inc. and Bayer HealthCare achieved positive results from two parallel Phase III studies in patients with the neovascular form of age-related macular degeneration (wet AMD), with all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution). Both trials successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month. The primary endpoint was statistical non-inferiority in the proportion of patients who maintained (or impro...